PERSEUS Trial Adverse Events and Safety Profiles
Brea C. Lipe, MD explains common grade 3 and grade 4 adverse events observed in the PERSEUS trial.
EP: 1.Unmet Needs and Standards of Care in Multiple Myeloma
EP: 2.A Unique Drug Delivery Technology for MM
EP: 3.PERSEUS Trial Design and Overview
EP: 4.PERSEUS Trial Outcome Analysis
EP: 5.PERSEUS Trial Adverse Events and Safety Profiles
EP: 6.Integrating New Approaches to MM Treatment
EP: 7.Closing Perspectives on MM Treatment and Care
Summary
In terms of safety, the PERSEUS trial did not reveal any new or unexpected adverse events. The most common side effects were thrombocytopenia and neutropenia, consistent with the known safety profile of Dara-VRd which tends to have higher rates of cytopenia compared to VRd alone. Notably, this trial was conducted during the COVID-19 pandemic. Higher rates of infectious complications like pneumonia were seen in the Dara-VRd arm compared to VRd alone. This reinforces our understanding that quadruplets can increase susceptibility to infections, though we are learning how to better mitigate these risks. Overall, the safety profile aligned with expectations for Dara-VRD, with managing cytopenia and infections as key considerations.
Summary was AI-generated and edited for clarity.
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More
